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Abstract. 
Mutations in fukutin related protein (FKRP) underlie a group of muscular dystrophies associated 
with the hypoglycosylation of α-dystroglycan (α-DG), a proportion of which show central 
nervous system involvement. Our original FKRP knock down mouse (FKRP
KD
) replicated many 
of the characteristics seen in patients at the severe end of the dystroglycanopathy spectrum but 
died perinatally precluding its full phenotyping and use in testing potential therapies. We have 
now overcome this by crossing FKRP
KD 
mice with those expressing Cre recombinase under the 
Sox1 promoter. Due to our original targeting strategy this has resulted in the restoration of Fkrp 
levels in the central nervous system but not the muscle, thereby generating a new model 
(FKRPMD) which develops a progressive muscular dystrophy resembling what is observed in 
limb girdle muscular dystrophy. Like-acetylglucosaminyltransferase (LARGE) is a bifunctional 
glycosyltransferase previously shown to hyperglycosylate α-dystroglycan. In order to investigate 
the therapeutic potential of LARGE up-regulation we have now crossed the FKRPMD line with 
one overexpressing LARGE and show that, contrary to expectation, this results in a worsening of 
the muscle pathology implying that any future strategies based upon LARGE up-regulation 
require careful management. 
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Introduction. 
Dystroglycan (DG) forms the central component of the dystrophin associated protein complex 
and has been attributed with a primary role in the deposition, organisation and turnover of 
basement membranes (1-7).  It is composed of two subunits, both of which are encoded by the 
DAG1 gene: β-DG, a transmembrane protein and α-DG, a highly glycosylated peripheral 
membrane protein (l).  The primary sequence of α-DG predicts a molecular mass of 72kDa: 
however, due to extensive post-translational glycosylation the final molecular weight is around 
156kDa in skeletal muscle (8).  The O-linked glycan chains of the central mucin domain of α-DG 
mediate binding to basement membrane ligands including laminin (9), perlecan (10) agrin (11-
13), neurexin in the brain (14), pikachurin in the eye (15) and Slit (16) by interaction with the 
laminin LG (laminin globular) domains (17,18) and their loss from the central mucin domain of 
α-DG is considered to be central to the pathogenesis of a subgroup of congenital muscular 
dystrophies (CMDs), the dystroglycanopathies (7,19-21).  
 
To date at least 15 genes have been implicated in the glycosylation and/or processing of αDG, 
which now include POMT1 (PROTEIN O-MANNOSYL-TRANSFERASE 1) (22), POMT2 
(PROTEIN O-MANNOSYL-TRANSFERASE 2) (23), POMGNT1 (PROTEIN O-MANNOSE 
BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE) (24), LARGE (25-27), FKT 
(FUKUTIN) (28), FKRP (29,30), DPM2 (DOLICHYL-PHOSPHATE 
MANNOSYLTRANSFERASE POLYPEPTIDE 2), DPM3 (DOLICHYL-PHOSPHATE 
MANNOSYLTRANSFERASE POLYPEPTIDE 3) (31), ISPD (ISOPRENOID SYNTHASE 
DOMAIN CONTAINING) (32,33), GTDC2 (GLYCOSYLTRANSFERASE-LIKE DOMAIN 
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CONTAINING 2) (34), TMEM5 (TRANSMEMBRANE PROTEIN 5) (35), B3GNT1 (BETA-1,3-N-
ACETYLGLUCOSAMINYLTRANSFERASE 1) (36), DOLK (DOLICHOL KINASE) (37), 
SGK196 (SUGEN KINASE 196) (38) and GMPPB (GDP-MANNOSE PYROPHOSPHORYLASE 
B) (39). Mutations in these genes are often associated with a wide clinical spectrum of 
phenotypes, including severe CMD and structural brain defects as exemplified by Walker 
Warburg syndrome (WWS) OMIM 236670, Muscle Eye Brain disease (MEB) OMIM 253280, 
Fukuyama CMD (FCMD) OMIM 253800, and congenital muscular dystrophy type 1D 
(MDC1D) OMIM 608840).  Whilst the precise pathway in which these proteins function is 
unclear, recent work suggests that SGK196 is a glycosylation specific O-mannose kinase and that 
FKRP, FKTN, TMEM5, B3GNT1 and LARGE all contribute to the generation of an extracellular matrix 
binding moiety on the resulting phosphorylated core M3 glycan (38). The loss of matrix binding is 
associated with a profound reduction in the binding of either IIH6 and/or VIA4-1 antibodies to α-
dystroglycan (40). In addition a deficiency of Dol-P-Man synthase subunit DPM2 and DPM3 
indicates a possible link between the congenital disorders of glycosylation and the 
dystroglycanopathies.  However, it is mutations in FKRP that underlie LGMD2I, which is one of 
the most frequent autosomal recessive forms of LGMD (Limb girdle muscular dystrophy) in the 
UK, reported to make up 19.1% of the total LGMD group, with a prevalence of 0.43/100 000 .  
 
We previously generated a mouse model for FKRP related disease by inducing a knock-down in 
Fkrp expression via the insertion of a floxed Neomycin cassette into intron 2 of the mouse Fkrp 
gene (FKRP
KD
). This resulted in perinatal lethality due to central nervous system involvement 
and whilst this model has proved useful in studies of disease pathogenesis, it is limited in regard 
to its potential for evaluating potential therapies aimed at restoring muscle function. In order to 
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overcome this we have now crossed the FKRP
KD
 line of mice with one expressing Cre 
recombinase under the control of the Sox1 (Sex determining region Y-box 1) promoter, and 
show here that this strategy successfully restored Fkrp activity in the brain but not muscle.  This 
new line, henceforth referred to as FKRPMD, lives a normal lifespan and begins to show muscle 
damage at around 6 weeks of age and develops a progressive muscular dystrophy by 12 weeks, 
thereby representing a new mouse model of the less severe end of the dystroglycanopathy 
spectrum.   
 
Whilst there have been two recent reports of the successful restoration of functional 
glycosylation and amelioration of the muscle pathology by AAV (Adeno-Associated Virus) 
vectors carrying either FKRP (41) or fukutin (42), one of the most promising forms of therapy 
proposed in recent years for the dystroglycanopathies is the up-regulation of LARGE; a 
bifunctional glycosyltransferase that alternately transfers xylose and glucuronic acid to generate 
a heteropolysaccharide that confers α-dystroglycan with its ligand binding properties (43). This 
is based on observations showing that LARGE is able to restore α-dystroglycan glycosylation 
and functional laminin binding to cells taken from patients with congenital muscular dystrophy 
(FCMD, MEB and WWS), seemingly irrespective of the gene involved (44). Whilst this 
response may be dependent on the availability of O-mannosyl phosphate acceptor sites (32), this 
strategy is still considered as being potentially useful for a wide range of patients. We have 
previously shown that in mice, over-expression of LARGE on a wild type background induces 
no overt pathology and is only associated with a minor loss of force in response to eccentric 
exercise in older mice, supporting the idea that increasing levels of this glycosyltransferase may 
represent an important therapeutic approach (45).  However, it remains crucial to test such a 
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strategy on a disease background and in order to do this we crossed our newly generated 
FKRPMD
 
mouse line with one of the original LARGE overexpressing lines (45). Somewhat 
surprisingly we report that this fails to ameliorate the phenotype and in a proportion of mice 
leads to a worsening of the disease process despite a marked increase in dystroglycan 
glycosylation implying that any future strategies based upon LARGE up-regulation require 
careful management.  
 
Results 
Restoration of Fkrp levels in the central nervous system prevents the perinatal lethality of 
FKRP
KD
 mice.  
FKRP
KD
 mice have a significant reduction in Fkrp expression in the muscle and brain, compared 
to wild type mice, which we attributed to the insertion of the floxed Neomycin cassette into 
intron 2 (46).  Since we believed that central nervous system involvement was responsible for the 
perinatal mortality, we set out to restore Fkrp expression in the central nervous system by 
crossing the FKRP
KD
 line with one expressing Cre recombinase under the Sox1 promoter. 
FKRP
KD
 mice expressing the Sox1 Cre transgene are henceforth referred to as FKRPMD.  This 
cross should delete the neomycin cassette from exon 2 in neurectoderm derived tissues. Since 
defects in the pial basement membrane due to a loss of α-dystroglycan are thought to be central 
to the brain phenotype of FKRP
KD 
mice (46,47) we examined paraffin wax embedded coronal 
sections of the cortex of newborn mice. These sections showed a clear disruption of cortical 
architecture in the FKRP
KD
 (Figure 1B) but no overt abnormalities in the FKRPMD mice, the 
latter of which were comparable to wild type (Figure 1A and C). IIH6 immunolabelling at the 
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pial basement membrane of the FKRPMD was comparable to that of WT (Figure 1A and C) but 
not the FKRP
KD
 (Figure 1B) and immunolabelling of frozen sections with a pan laminin antibody 
showed that the disorganisation of the pial basement membrane apparent in FKRP
KD 
mice 
(Figure 1E) had been restored to that of WT in the FKRPMD (Figure 1D and F). In order to 
further confirm that this strategy was successful we undertook an analysis of muscle and brain 
tissue from the FKRPMD mice using quantitative RT PCR. This showed that whilst a marked 
reduction in Fkrp transcript levels was still apparent in the muscle of FKRPMD mice, levels had 
been restored to that of wild type in the brain (Figure 1G). We previously showed that the 
percentage knock-down of Fkrp in the FKRP
KD
 mouse was similar in all tissues. Here we show 
that the percentage knock-down of Fkrp in the muscle of the FKRPMD was similar to that seen in 
the brain of the FKRP
KD
 at E15.5 (Figure 1H). 
 
Reduced Fkrp levels in skeletal muscle are associated with a progressive muscular 
dystrophy.  
FKRPMD male mice were shown to have a 12 and 20 week body weight not significantly 
different from control mice although female body weight was reduced at 20 but not 12 weeks 
relative to controls (Figure 2A). The lifespan and general behaviour of FKRPMD mice was 
indistinguishable from their wild type littermates.  
Haematoxylin and eosin stained sections of newborn FKRPMD muscle showed no evidence of 
muscle fibre necrosis either in the fore or hindlimb muscles (data not shown). However, by 6 
weeks of age occasional areas of small basophilic regenerating fibres and inflammatory 
infiltrates could be seen in the FKRPMD gastrocnemius (Figure 2C). This feature was quite 
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variable between individuals with some mice showing only minimal evidence of any pathology 
at this age. By 12 weeks of age both the gastrocnemius (Figure 2E) and the diaphragm (data not 
shown) of all FKRPMD mice exhibited fibre degeneration characterised by sarcoplasmic 
hyalinisation, loss of cross striations, and sarcoplasmic fragmentation and frequent groups of 
small, regenerative myofibres, with large, centralised nuclei and a granular pale basophilic 
cytoplasm (Figure 2 E). Small infiltrates of macrophages, lymphocytes and rare plasma cells, 
were observed to invade the interstitium and infiltrate necrotic myofibres. At 30 weeks there was 
evidence of an attenuati n of muscle fibre degeneration and regeneration with clusters of 
basophilic regenerative fibres being only occasionally evident together with rare, interstitial 
lymphoplasmacytic foci.  Representative images of the diaphragm, gastrocnemius and 
quadriceps at 30 weeks are shown in Figure 2 G - K. 
Interestingly, the soleus of the FKRPMD showed evidence of only minimal damage even at 30 
weeks of age, reflected by the low percentage of central nucleation which is a marker of previous 
rounds of degeneration and regeneration (Figure 2 L-M).  This parameter nonetheless increased 
between 12 and 30 weeks of age in all three muscles (gastrocnemius (48.9% to 57.3%), soleus 
(5.6% to 20.9%) and diaphragm (32.4% to 40.7%), with a Generalised Estimating Equations 
model showing that age, muscle and genotype were significant interacting factors affecting the 
percentage of centrally nucleated muscle fibres (Figure 2 L-M).  In contrast to previous findings 
in the dystrophin deficient mdx mouse, the diaphragm did not seem to be more severely affected 
than the limb muscles. Muscle sampled from wild type littermates at either 12 or 30 week time 
points was histologically unremarkable, exhibiting normal histopathological changes for mice of 
this genetic background i.e. the presence of minimal, rare, interstitial, lymphoplasmacytic 
infiltrates.   
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A reduction in α-dystroglycan glycosylation is associated with an alteration in laminin α2 
and α4 expression. 
The skeletal muscle of the FKRPMD mice displayed a near absence of immunolabelling with the 
IIH6 antibody relative to wild type littermates at 30 weeks of age (Figure 6B), with Western 
blotting further confirming the absence of functional glycosylation as judged by the absence of 
the IIH6 epitope and also showed that β-dystroglycan was unchanged (Figure 3G).  
Immunolabelling for laminin α2 which has previously been shown to be variably reduced in 
cases of LGMD2I (48), was shown to be increased on some fibres but decreased on others 
relative to WT controls in the FKRPMD at 12 weeks. Those fibres with a higher level tended to be 
associated with areas of increased cellular activity, whilst larger fibres showed either a slight 
decrease or similar levels to that of WT controls (Figure 3A-F). The application of a look up 
table to these images shows this variation more clearly (Figure 3H,I).  
Laminin α4 has previously been shown to be up-regulated in the basement membranes of blood 
vessels, the perineurium of intramuscular nerves, and isolated regenerating muscle fibres of 
laminin α2 deficient mice (dy/dy) (49). In wild type controls laminin α4 localised to the 
capillaries, nerves and neuromuscular junctions (Figure 4A,C,D), however in the FKRPMD at 12 
weeks of age laminin α4 was additionally increased at the sarcolemma of small groups of fibres. 
By 30 weeks of age a higher proportion of fibres showed laminin α4 at the sarcolemma than at 
earlier ages (Figure 4D,F). This was the case for each of the muscles examined (diaphragm, 
quadriceps and triceps). This up-regulation was not specifically associated with regenerating 
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fibres as determined by immunolabelling with developmental myosin which only labelled very 
few fibres at either 12 or 30 weeks.  
 
The overexpression of LARGE leads to a shortened lifespan and worsening of the FKRPMD 
phenotype. 
Previous work indicated that the upregulation of LARGE could be beneficial in the 
dystroglycanopathies (44,50,51). Contrary to expectation FKRPMD
 
overexpressing LARGE 
(FKRPMDLARGE) had a reduced lifespan in contrast to FKRPMD
 
mice - a subsequent 
deterioration in the overall condition of FKRPMDLARGE mice led to some mice being culled at a 
humane end point which was often around 27 weeks of age.  FKRPMDLARGE displayed normal 
behaviour, aside from an abnormal stance and a partial collapse of the leg extensor reflex, a 
feature not observed in the FKRPMD mice.   
In keeping with the more severe phenotype, FKRPMDLARGE mice displayed a more severe 
pathology than age-matched FKRPMD controls at 12 weeks as indicated by a marked variation in 
fibre size, centrally nucleated muscle fibres (Supplementary Figure 1) and significant increases 
in the number of split fibres (Figure 7D).  A Generalised Estimating Equations statistical model 
showed that age, genotype and muscle were significant factors affecting the percentage of 
centrally nucleated fibres suggesting that LARGE upregulation significantly increased the 
percentage of centrally nucleated fibres at both 12 and 30 weeks of age, relative to the FKRPMD 
(Figure 7). There was in addition a more pronounced expansion of the interstitium with small to 
moderate amounts of variably-mature fibroadipose tissue and a substantial inflammatory 
component, which infiltrated both the interstitium and necrotic muscle fibres and was comprised 
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of moderate numbers of neutrophils, macrophages and lesser numbers of lymphocytes and 
plasma cells (Supplementary Figure 1).  This was seen in all muscles examined at 12 weeks of 
age, including the diaphragm, gastrocnemius, tibialis anterior (TA) and soleus (Supplementary 
Figure 1).  
 
In those mice that survived to 30 weeks there was a noticeable hypertrophy of many fibres, 
(relative to the FKRPMD).  Individual (predominantly centrally nucleated) muscle fibres were 
occasionally surrounded by moderate to large amounts of compact, fibrous connective tissue and 
infiltrates of fat (Figure 5B, D, F, H), with some muscle fibres mineralised.  At this later time 
point as in the FKRPMD, there was minimal degeneration and necrosis although the inflammatory 
infiltration was more marked with infiltration by both neutrophils and macrophages in the 
diaphragm and gastrocnemius. Alizarin red staining showed a marked increase in the presence of 
large calcium deposits in the FKRPMDLARGE relative to the FKRPMD mice (Figure 5 I-K). This 
was the case for all the muscles examined including the soleus. Alizarin red staining was also 
markedly worse in the diaphragm of the FKRPMDLARGE mice, relative to the gastrocnemius at 
12 weeks of age, a difference between these muscles that was not evident in the FKRPMD
 
mice at 
this age. 
 
FKRPMDLARGE
 
mice display an increase in IIH6 labelling and laminin deposition. 
The glycosylation of α-DG as assessed by IIH6 immunolabelling was increased in all 
FKRPMDLARGE muscles examined (diaphragm, gastrocnemius and soleus) relative to wild type 
mice (Figure 6 shows the gastrocnemius), and levels were comparable to that of the original 
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LARGE transgenic line (data not shown). Laminin α2 deposition at the basement membrane was 
increased in FKRPMDLARGE mice relative to FKRPMD mice or wild type.  Whilst regenerating 
fibres are known to express higher levels of basement membrane proteins, this increase extended 
beyond the clusters of small regenerating fibres. The number of fibres with sarcolemmal 
labelling for laminin α4 was also increased in the FKRPMDLARGE mice relative to FKRPMD 
mice (Figure 6). Western blot analysis of muscle at 15-20 weeks showed that transgene 
expression in either the wild type or FKRPMD gives rise to an increase in laminin binding relative 
to wild type confirming that expression of the transgene led to the hyperglycosylation of α-DG. 
(Figure 7). 
 
FKRPMDLARGE
 
mice show a physiological deficit relative to the FKRPMD. 
To compare the functional properties associated with a knock-down of Fkrp and how this was 
altered by the transgenic expression of LARGE we subjected the TA muscles of anaesthetized 
mice to a protocol of 10 eccentric (lengthening) contractions in situ. The protocol induced a 15% 
stretch during each of 10 maximal isometric contractions stimulated 2 minutes apart. Isometric 
tetanic force was measured prior to each stretch and expressed as a percentage of baseline 
isometric force. FKRPMD mice showed a similar resistance to eccentric contraction-induced 
injury to non-transgenic age-matched wild type controls (101.1% and 118.5% of baseline 
isometric force generated in the last contraction respectively) with only a small significant drop 
in force after contraction 10. However, FKRPMDLARGE showed a significant reduction in their 
resistance (72.5% of baseline isometric force in the last contraction) relative to controls (118.1% 
of baseline isometric force in the last contraction) confirming that the worsened phenotype 
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evident on histological analysis had translated into a measurable physiological deficit (Figure 8). 
No significant differences were observed for the force-frequency relationship between any of the 
genotypes (data not shown). 
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Discussion. 
LGMD2I is one of the most frequent autosomal recessive forms of LGMD and in the UK has 
been reported to make up 19.1% of the total LGMD group with a prevalence of 0.43/100 000 
(52,53). Whilst the spectrum of disease in the dystroglycanopathies is wide, a significant 
proportion of patients are affected by relatively mild limb girdle muscular dystrophies without 
any central nervous system involvement, making it a good target for developing therapies. In 
order to gain insight into the disease pathogenesis of FKRP associated muscular dystrophy we 
previously generated a mouse model with a knock-down in Fkrp (FKRP
KD
) that displayed a 
muscle eye brain phenotype. Whilst this model provided insight into the eye and brain phenotype 
(46), it died around the time of birth due to the severity of central nervous system involvement 
(47) and so was less useful for investigating the consequences of a reduction in Fkrp on postnatal 
muscle growth and function and for evaluating therapeutic strategies aimed at ameliorating the 
skeletal muscle phenotype.  
In mammals, the cortex develops in an “inside out” manner, with migration of post mitotic 
neurons from the proliferative neuroepithelium (ventricular zone) to the cortical plate with each 
layer of post-mitotic neurons forming a more superficial layer than the last (54). The majority of 
neuronal migration is radial and is mediated by a scaffold of radial glial cells which extend from 
the ventricular zone (where their cell bodies are located) to the pial basement membrane. In the 
present report we addressed the perinatal lethality of the FKRP
KD
 mouse by crossing it with a 
transgenic line in which Cre recombinase is expressed under control of the Sox-1 promoter to 
generate FKRP
KD
/Sox1Cre mice which we refer to as FKRPMD. The Sox1 promoter is known to 
drive expression in the neuroectoderm early during development (55) and this cross resulted in 
mice with wild type Fkrp transcript levels in the brain, a restoration of IIH6 immunolabelling at 
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the pial basement membrane and normal cortical architecture. Previous work has indicated that 
the restoration of glial rather than neuronal dystroglycan that plays a crucial role in forebrain 
development (56) and the restoration of the pial basement membrane and cortical organisation 
we observed was therefore consistent with these observations. As expected there remained an 
approximate 80% reduction of Fkrp transcript levels in the skeletal muscle which was associated 
with the loss of the laminin binding epitope IIH6 as previously reported for the FKRP
KD
 line 
(21).  
Despite the absence of the laminin binding IIH6 epitope from birth, the onset of muscle 
degeneration first occurred around 6 weeks of age in the majority of animals and by 12 weeks of 
age a marked pathology was evident in all FKRPMD mice. Western blot analysis confirmed that 
the IIH6 epitope was completely absent. This also resulted in the loss of laminin binding which 
is consistent with previous studies in the LARGEmyd, POMGnTnull and POMT1 mice that also 
report a reduction in the ability to bind laminin and develop a severe muscular dystrophy (57).  
In contrast, the muscle of a mouse model of FCMD (FCMD Hp
-
) which contains a 
retrotransposal insertion in the mouse fukutin ortholog also failed to label with IIH6 but retained 
the ability to bind laminin albeit at 50% of the levels of controls. This mouse did not display any 
signs of a muscular dystrophy suggesting the existence of a threshold of glycosylation/laminin 
binding activity which was met in the FCMD mice (58) but not in the LARGEmyd and 
POMGnTnull or our FKRPMD mice.  
All laminin isoforms with LN (Laminin N-terminal) domains play an integral role in basement 
membrane assembly by anchoring to cell surfaces, self polymerizing, and binding to nidogen and 
collagen IV (1). Laminin 211 is the major laminin isoform present in skeletal muscle and is 
reduced albeit not invariably in the skeletal muscle of dystroglycanopathy patients. A variation in 
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laminin α2 immunolabelling was also observed in FKRPMD mice at 12 weeks with higher levels 
of labelling apparent on small regenerating fibres whilst the majority of larger fibres either 
showed similar levels to that of controls or a reduction implying that a reduction in glycosylation 
may influence the turnover and/or stability of laminin 211 in the basement membrane of mature 
muscle fibres. Interestingly, there was no obvious reduction in perlecan in the FKRPMD mice 
when compared to wildtype mice (data not shown) despite previous reports of a reduction in the 
perlecan-binding activity and its mis-localisation in the brains of Largemyd and dystroglycan null 
mice (59). However, it may be that laminin α2 rather than perlecan is the main binding partner 
for α-dystroglycan in muscle, indeed the binding properties of α-dystroglycan are known to be 
different in brain and muscle (60).   
We observed a redistribution of laminin α4 in the FKRPMD muscle which has also been reported 
in laminin α2 deficient mice (49). Laminin α4 normally locates to the basement membranes of 
blood vessels, the endoneurium of the intramuscular nerves, and the neuromuscular junction in 
neonatal skeletal muscle (49). In adult muscle it locates to the perineurium of adult peripheral 
nerve. Laminin α4 lacks the ability to self-polymerise (61) due to the absence of the N-terminal 
domain, and consequently has the potential to interfere with basal lamina formation where 
laminin α2 is a major component. It also displays a low affinity binding for α-dystroglycan, 
sulfatides, and integrins α6β1 and α7β1 (62), properties that suggest it may be an ineffective 
substitute for laminin α2. However, the up-regulation of laminin α4, which is also a feature of 
laminin α2 deficiency may nonetheless be of functional significance since recent work in the 
zebra fish suggests that its up-regulation in damaged fibres contributes to fibre survival (63). 
Interestingly, an increase in the number of fibres with laminin α4 at the sarcolemma was 
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observed to increase with age in the FKRPMD, implying that a similar scenario may apply to our 
mice.  
LARGE is a bifunctional glycosyltransferase thought to be essential for conferring α-
dystroglycan with the ability to bind laminin. The over-expression of LARGE has been shown to 
increase-DG glycosylation in both wild type and cells from dystroglycanopathy patients, 
irrespective of their primary gene defect (44). Whilst more recent work now demonstrates that 
the ability of LARGE to hyperglycosylate α-dystroglycan is dependent on the availability of O-
mannosyl phosphate acceptor sites and correlates with the severity of the clinical phenotype (32); 
this strategy is still considered as being potentially useful for a wide range of patients. 
Furthermore, the viral delivery of LARGE to skeletal muscle in animal models of 
dystroglycanopathy has been reported to have identical effects in vivo, suggesting that the 
restoration of functional glycosylation may be a valuable therapeutic approach in this group of 
disorders (44,58). We previously generated a number of transgenic lines overexpressing LARGE 
(45) and have now crossed one of these lines with our FKRPMD
 
mice.  On a wild type 
background the up-regulation of LARGE is not associated with any muscle fibre degeneration 
but there is a mild loss of force upon eccentric exercise in the TA of older animals (45), 
suggesting some form of subtle abnormality in basement membrane turnover occurs over an 
extended time period (64).  However, when we crossed the FKRPMD line with the LARGE 
transgenic the pathology of the FKRPMD
 
phenotype worsened with an increased percentage of 
centrally nucleated fibres in all the muscles examined relative to the FKRPMD. Additional 
features such as calcium deposits, evidence of fibrosis and replacement of muscle fibres by 
adipocytes were also more evident in the presence of the LARGE transgene and the soleus 
muscle which was largely spared in the FKRPMD showed clear evidence of pathology in the 
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presence of the LARGE transgene. The promoter driving the LARGE transgene expresses at 
equivalent levels in both slow and fast fibres therefore these observations reflect a differential 
pattern of muscle involvement in the FKRPMD. 
Whilst there are several differences between our study and those which previously indicated that 
the up-regulation of LARGE would be beneficial such as the method of gene delivery, promoter 
used to drive expression, and animal model, the most significant difference relates to the timing 
over which LARGE was overexpressed, and the duration of the period of observation. For 
example, LARGE was introduced into the Large
myd
, POMGnT1
-/-
 and FCMD Hp
-
 mice via AAV 
vectors at postnatal data 2-4 and then evaluated 4 weeks later (44,58).  More recently Yu et al 
(50) injected AAV9-LARGE (expression driven by the β-actin promoter) via into the newborn 
heart and adult tail vein of POMGnT1null and LARGEmyd mice and looked at expression at 2 
months (newborn injections) and 1 month (adult tail vein injections) later. These authors noted 
significant improvement of the histological appearance of the muscle and amelioration of the 
phenotype. Barresi et al (44) also administered LARGE to older Large
myd
 mice, aged between 12 
days and 5 weeks but reported that this was associated with muscle inflammation and a loss of 
IIH6 immunolabelling (LARGE up-regulation) as the mice aged.   
These findings are in marked contrast to those of our own using transgenesis and would seem to 
imply that the time period over which LARGE is up-regulated and/or the stage of development 
that it is initiated determine the outcome. Here we have shown that despite the restoration of 
laminin binding in the FKRPMDLARGE there was a significant loss of force in response to 
eccentric exercise which was not seen in the FKRPMD confirming that the overexpression of 
LARGE had worsened the phenotype as indicated by the histological analyses. The reasons for 
this remain unclear however, it is possible that on a disease background, specifically one in 
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which the glycosylation of α-dystroglycan is reduced or absent, LARGE not only targets 
additional proteins, the hyperglycosylation of which is detrimental to muscle, but may also lead 
to a functionally relevant alteration in the glycosylation pattern of α-DG itself. In support of 
these two concepts it has previously been shown that LARGE over-expression in α-DG-deficient 
cells leads to the expression of the IIH6 epitope (65) and that LARGE acts not only on the O-
mannose glycans but also complex N-glycans and mucin O-GalNAc (N-Acetylgalactosamine) 
glycans of α-DG (66). Previous work in ES (Embryonic Stem) cells indicates that neither 
integrin nor dystroglycan are individually required for assembly of the basement membrane but 
they do regulate both their own expression and that of other basement membrane components 
(67). It is therefore possible that this system of regulation is perturbed by an altered pattern of α-
dystroglycan glycosylation, perhaps by compromising the turnover process of the basement 
membrane. Finally it should also be noted that as a consequence of the transgenic approach 
adopted here, the FKRPMDLARGE mice are on a different background to the FKRPMD mouse. 
However, we consider this an unlikely cause of the worsened phenotype since histological 
evaluation of wildtype LARGE overexpressing mice on this new genetic background failed to 
identify any evidence of a dystrophic pathology. 
Our work reports the first transgenic up-regulation of LARGE on a disease background. Whilst 
the onset of disease in the FKRPMDLARGE mice was not markedly different to the FKRPMD, 
suggesting that the over-expression of LARGE did not adversely affect the early stages of 
muscle development, several aspects of the disease process were significantly worse. The 
reasons for this are unclear at the present time, but emphasise the value of determining the effect 
of overexpression on a disease background over an extended period and suggest that any 
therapeutic approach involving LARGE up-regulation requires careful management.  
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Materials and Methods. 
Generation of FKRP-Neo
Tyr307Asn+/+Sox1Cre
 mice (FKRPMD)  
All animal experiments were carried out under license from the Home Office (UK) in accordance 
with The Animals (Scientific Procedures) Act 1986 and were approved by Royal Veterinary 
College ethical committee. The FKRP-Neo
Tyr307Asn+/+
 (FKRP
KD
) mouse colony (47) was crossed 
with a second transgenic line expressing Cre recombinase throughout the developing neural tube 
under the Sox1 promoter (a kind gift from Professor Liz Robertson, Sir William Dunn School of 
Pathology, Oxford U.K.) (68).  Briefly FKRP-Neo
Tyr307Asn+/-
 were crossed with Sox1Cre mice 
and the resulting FKRP-Neo
Tyr307Asn+/-Sox1Cre
 mice were bred with FKRP-Neo
Tyr307Asn+/-
 mice 
which generated FKRP-Neo
Tyr307Asn+/+Sox1Cre
 mice, referred to as FKRPMD.  Thus, the first cross 
introduced the Sox1Cre transgene into the background of the FKRP
KD
 colony, while the second 
first generation cross generated the FKRPMD
 
offspring at a frequency of approximately 7%.  
FKRPMD
 
mice are fertile and breeding them with FKRP-Neo
Tyr307Asn+/-
 mice increased the 
incidence of mice to approximately 14%.  However, pairing two FKRP-Neo
Tyr307Asn+/-Sox1Cre
 
heterozygote mice resulted in high pre-weaning losses, with a number of offspring suffering 
from hydrocephalus.  
 
Generation of  FKRP-Neo
Tyr307Asn+/+Sox1CreLARGE 
(FKRPMDLARGE).  
The following strategy was used to generate FKRPMD, FKRP
KD 
and FKRPMD LARGE mice. 
FKRP-Neo
Tyr307Asn+/-Sox1Cre 
mice were crossed with a transgenic mouse line (LV5) overexpressing 
human LARGE (45) to introduce the LARGE transgene into the background of the FKRPMD
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mice.  FKRP-Neo
Tyr307Asn+/-Sox1CreLARGE
 mice were then crossed with FKRP-Neo
Tyr307Asn+/- 
to 
generate FKRP-Neo
Tyr307Asn+/+Sox1CreLARGE 
mice, henceforth referred to as FKRPMDLARGE mice. 
 
Genotyping FKRPMD
 
offspring 
Offspring were genotyped by PCR analysis using either ear or tail biopsies.  Genomic DNA from 
the mouse tissue was prepared by digestion in Direct PCR Lysis Ear or Tail buffer (Eurogentec) 
respectively containing 0.2mg/mL Proteinase K (Roche Diagnostics) at 55°C overnight.  The 
Proteinase K was heat inactivated at 85°C for 30 minutes and PCR was performed with the crude 
DNA lysate using Biomix Red PCR Kit (Bioline) with the following multiplex primers for Fkrp 
(FKRP-F: CTAGGAGGTTGAGGATGATGG, FKRP-R: GTTGTGCTTAAACCACCTTC, and 
FKRP-NeoF:GGTGGATTAGATAAATGC), Cre recombinase (Cre-F: 
CCCAGGCTAAGTGCCTTCTC and Cre-R: CCAGGTTCGTTCACTCATGG) and LARGE 
(Large-F:TAATACGACTCACTATAGGG Large-R: AAGGTTCTCGCTGTCTCC).   
 
Histology and Immunocytochemistry 
For standard histochemistry, newborn mice were collected and fixed in Bouins (Sigma) and 
transferred to 70% ethanol prior to processing and embedding in paraffin wax. Samples were 
serially sectioned at 5µm, with sections collected onto charged slides (Superfrost Plus, VWR), 
rehydrated and stained with haematoxylin and eosin, using standard methods. For 
immunohistochemistry sections were deparaffinised and rehydrated prior to incubation with anti  
α-dystroglycan (IIH6, Millipore) diluted in phosphate buffered saline containing 0.05% tween 20 
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(Sigma) for 1 hour at room temperature.  Visualisation of the IIH6 was performed using the 
Envision system (DAKO). 
 
Alternatively, muscle and brain samples were frozen in isopentane cooled in liquid nitrogen and 
10µm sections were cut using a Bright Cryostat.  These were then stained with haematoxylin and 
eosin using standard methods to evaluate general tissue pathology and calculate the percentage 
of centrally located nuclei.  Additionally, Alizarin Red staining was performed to identify 
calcium deposits.  Images of newborn mouse heads and muscles stained with these histochemical 
methods were digitally captured using a DM4000B upright microscope (Leica, Germany) 
interfaced with a DC500 colour camera (Leica) using the Leica Application Suite (Leica 
Microsystems) software provided and compiled into figures using Photoshop CS4 or CS5 
(Adobe, U.S.A.).  Figures were compiled using Photoshop CS (Adobe, U.S.A.).  All 
observations are based on a minimum of n=3 (of either sex), and representative images are 
shown.  Counts of centrally nucleated muscle fibres were made across an entire section from 
each individual mouse muscle (n=3 for wildtype, FKRPMD and FKRPMDLARGE mice at 12 and 
30 weeks of age) randomly chosen from the mid-region of each muscle, with the total number of 
fibres counted numbering approximately 500, 1500 and 2000 muscle fibres in the soleus, 
diaphragm and gastrocnemius respectively.  The incidence of split muscle fibres was based on 
counts of approximately 2000 muscle fibres across an entire section from the mid-belly region of 
12 week old wildtype, FKRPMD and FKRPMDLARGE gastrocnemius (n=3 for all genotypes). 
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For immunohistochemical analysis of muscle and brain, cryosections were immunolabelled with 
rabbit anti pan-laminin (Sigma-Aldrich), rat anti laminin α2 (4H8, Abcam), goat anti-laminin α4 
(R&D Systems) and the IIH6 antibody against a glycosylated epitope of α-DG (Millipore).  This 
was followed by anti-rat/rabbit/goat tagged with Alexa 488 or 594 (Molecular Probes) for 30 
minutes, with the exception of IIH6 which was labelled with anti-IgM biotinylated antibody (30 
minutes) followed by streptavidin conjugated with Alexa 488/594 (30 minutes).  Nuclei were 
stained with Hoechst 33342 (Sigma-Aldrich). All dilutions and washes were made in phosphate 
buffered saline. Sections were mounted in aqueous mountant and viewed with epifluorescence 
using a DM4000B upright microscope (Leica, Germany).  Images were digitally captured with 
an Axiovision mRM monochrome camera, (Zeiss, UK) and compiled using Photoshop CS 
(Adobe, U.S.A.). Where direct comparisons have been made, fluorescent images were captured 
with equal exposure and have had equal scaling applied. All observations are based on a 
minimum of n=3 (of either sex), representative images are shown.  
 
qRTPCR analysis. 
Brain and muscle were dissected out and homogenised with liquid nitrogen using a mortar and 
pestle and the lysate passed through a QiaShredder
®
(Qiagen). RNA was isolated from the 
homogenised tissue using an RNeasy
®
kit (Qiagen) and for muscle RNeasy
®
 Fibrous Tissue Kit 
(Qiagen) eluted with 30µl RNase free H2O. 1µg of RNA was reverse transcribed with 
Superscript
®
III Platinum for qRT-PCR kit (Invitrogen). qRT-PCR was performed on a 7500 
FAST Real-Time PCR system (Applied Biosystems) using aFAM
(tm)
 reporter dye system. For 
each reaction 0.8µl of cDNA was used as template in a PCR mix consisting of 1µl of primer mix, 
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10 ul TaqMan Universal PCR Mastermix (Applied Biosystems) and 8.2µl H2O.  The primers for 
the gene expression assays were sourced commercially from Applied Biosystems (FKRP 
Mm00557870_mL, GAPDH Mm99999915_gL).  Each experiment represents a minimum of n=4 
(of either sex) and all reactions were performed in triplicate. 
 
Western blotting and laminin overlay assay. 
Cell proteins were extracted in sample buffer consisting of 75 mM Tris–HCl, 1% SDS, 2-
mercaptoethanol, plus a cocktail of protease inhibitors (Roche). 30µg of soluble proteins were 
resolved using a NuPage Pre-cast gel (3–8% Tris-acetate; Invitrogen, USA) and then transferred 
electrophoretically to nitrocellulose membrane (Hybond-PVDF, GE Healthcare, UK. 
Nitrocellulose strips were blocked in 5% dried non fat milk in phosphate-buffered saline buffer, 
and then probed with the primary antibodies: anti mouse α-DG IIH6 (Millipore UK,cat,05-593) 
anti-mouse β-DG (Vector Labs, UK), at room temperature for 1 hour. After washing they were 
incubated with the appropriate HRP conjugated secondary antibody for one hour: anti-mouse-
IgM or anti-mouse-IgG (both from Jackson ImmunoResearch). After washing, membranes were 
visualized using chemiluminescence (ECL+Plus, GE Healthcare, UK). For the laminin overlay 
assay, nitrocellulose membranes were blocked for 1 hour in laminin binding buffer (LBB: 10 
mM triethanolamine, 140 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, pH 7.6) containing 5% non-fat 
dry milk followed by incubation of mouse Engelbreth-Holm-Swarm laminin (Invitrogen,USA) 
overnight at 4°C in LBB. Membranes were washed and incubated with anti rabbit laminin 
(Sigma, USA) followed by HRP-anti rabbit IgG (Jackson ImmunoResearch, USA). Blots were 
visualized using chemiluminescence (ECL+Plus, GE Healthcare,UK). 
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In situ/vivo muscle electrophysiology. 
Mice were surgically prepared as described previously (69,70). Contractions were stimulated in 
the TA muscle in situ via the surgically isolated common peroneal nerve. The TA muscle 
underwent a series of 5 submaximal isometric contractions as a warm up. Isometric force 
measurements were made over a range of stimulating frequencies and maximum isometric 
tetanic force (P0) was determined from the plateau of the force–frequency curve (20). After 
completing the final isometric contraction the optimum length (Lo) was measured with digital 
callipers and the muscle was allowed to rest for 5 min before the eccentric contraction protocol 
was initiated. A tetanic contraction was induced using a stimulus of 120 Hz (the frequency that 
resulted in P0 without causing fatigue during the contraction) for 700 ms. During the last 200 ms 
of this contraction, the muscle was stretched by 15% of Lo at a velocity of 0.75 Los
-1
 and relaxed 
at -0.75Los
-1
. The isometric tension recorded prior to the first stretch was used as a baseline. The 
muscle was then subjected to 10 eccentric contractions each separated by a 2 min rest period to 
avoid the confounding effect of muscle fatigue. The isometric tension prior to each stretch was 
recorded and expressed as a percentage of the baseline tension (69). The mouse was then 
euthanized and the muscle was carefully removed and weighed. 
 
Statistical analyses. 
Body weights were analysed with a Linear Mixed Effects Model and central nucleation counts 
were analysed with a General Estimating Equations model, both performed using SPSS Statistics 
(IBM, U.S.A).  The incidence of split fibres was analysed with a one-tailed Mann-Whitney test,  
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Muscle physiology data were analysed using a Repeated Measures One-way ANOVA with 
Tukey’s post-hoc comparison. 
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Figure Legends. 
Figure 1 Real time gene expression analysis of FKRP in brain and muscle and histological 
evaluation of FKRPMD brain. (A) IIH6 immunolabelling of haematoxylin stained coronal 
sections of FKRP
KD
 heterozygote (A), FKRP
KD
 (B) and FKRPMD (C) brains at P0. The cortical 
disorganisation evident in the FKRP
KD
 is no longer evident in the FKRPMD which now reflects 
that seen in the FKRP
KD
 heterozygote control. IIH6 immunolabelling can be seen at the pial 
basement membrane of the FKRP
KD
 heterozygote and FKRPMD but not the FKRP
KD
.  
Immunolabelling of the pial basement membrane with a pan laminin antibody (D-F) shows the 
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disorganisation at the intrahemispheric fissure in the FKRP
KD
, whereas in the FKRPMD (F) 
organisation is comparable to that of heterozygote FKRP
KD
 control (D). Scale bar in images A-D 
are 50µm.  Relative expression of FKRP (G,H).  Taq man (Applied Biosystems) RT-PCR probes 
were used to measure relative FKRP mRNA expression in brain and skeletal muscle of FKRPMD 
mice compared to age-matched wild type controls.  Expression levels were normalised against 
endogenous GAPDH mRNA expression. The percentage knock-down evident in the FKRP
KD
 
has been maintained in the FKRPMD as a comparison with the levels in the FKRP
KD
 brain at 
E15.5 show. Error bars represent SEM (n = 4). All samples were analysed as triplicate data sets. 
* P value = < 0.05 (two tailed t-test) ** P value < 0.005. Error bars represent ± SEM (n = 4).   
 
Figure 2. Body weight and histological analysis of muscle at 6, 12 and 20 weeks. (A) Mean 
body weights ± SEM of male and female wildtype (white) and FKRPMD (patterned) at 6 weeks 
(male WT n=8, male FKRPMD n=29; female WT n=14, female FKRPMD n=12), 12 (male WT 
n=10, male FKRPMD n=17; female WT n=14, female FKRPMD n=24) and 20 weeks of age (male 
WT n=7, male FKRPMD n=13; female WT n=6, female FKRPMD n=12).  Data were analysed 
with a Linear Mixed Effects Model performed using SPSS Statistics (IBM Corporation, U.S.A).  
This model showed that age was a significant factor affecting mouse body weight in both male 
and female mice, but genotype was not a significant factor affecting male body weight (p=0.245) 
although it was with respect to female body weight, with significance shown as follows: *0.01 
≤p<0.05, ** 0.001≤p<0.01. (B-K) Digital images of haematoxylin and eosin stained cryosections 
from wildtype (B,D,F,H,J) and FKRPMD (C,E,G,I,K) gastrocnemius (B-E, H-I) diaphragm (F-G) 
and quadriceps (J-K) at 6 (B-C), 12 (D-E) and 30 (F-K) weeks of age.  FKRPMD muscle shows 
evidence of inflammatory infiltrates and muscle fibre degeneration at 6 weeks of age (C), with 
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muscle fibre regeneration seen at 12 weeks of age (D).  At 30 weeks of age, centrally nucleated 
muscle fibres indicating previous regeneration cycles are seen in the FKRPMD diaphragm (G) and 
gastrocnemius (I).  Counts of central nucleation were carried out on transverse 10µm muscle 
cryosections of wildtype and FKRPMD diaphragm, gastrocnemius and soleus at 12 and 30 weeks 
of age - the muscle fibres with central nuclei were counted and expressed as a percentage of the 
total number counted (approximately 500 for the soleus, 1500 for the diaphragm and 2000 for the 
gastrocnemius).  The histogram in L shows the mean percentage of centrally nucleated muscle 
fibres ± SEM of wildtype (white) and FKRPMD (patterned) in the diaphragm, gastrocnemius and 
soleus at 12 and 30 weeks of age as indicated.  This data was analysed using a General 
Estimating Equations Model performed using SPSS statistics which showed that age, muscle and 
genotype were significant factors affecting the percentage of centrally nucleated muscle fibres.  
The output of this model is shown as a multiple line graph in M.  Scale Bars represent 50µm in 
B-K.  
 
Figure 3. Immunolabelling and Western blot analysis of FKRPMD muscle.  
Transverse 10µm cryosections from 12 week old wildtype (A,C,E) and FKRPMD (B,D,F) mouse 
triceps were labelled with Hoescht 33342 to visualise the nuclei (A-B) and an antibody against 
laminin α2 (C-D), with a colour composite shown in E-F.  Laminin α2 immunolabelling was 
variable in the FKRPMD with small clusters of fibres showing an increase relative controls whilst 
the majority of other fibres displayed either similar levels to controls or a slight decrease.  Scale 
bar represents 50µm.  Western Blotting analysis (G) of quadriceps from wildtype and FKRPMD 
mice shows IIH6 labelling, present in WT mice (lanes 3,4 and 5) was absent in FKRPMD mice 
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(lanes 1,2,6 and 7).  Each lane contains an extract from individual animals. β-DG (43kDa) which 
also acts as a loading control is shown to be unchanged in the FKRPMD.  The images shown in C 
and D) are shown using a look up table from Image J to emphasise the variation in intensity of 
laminin α2 immunolabelling across the section. J shows the scale used. 
 
Figure 4.  Laminin α4 immunolabelling of FKRPMD and wild type controls.   
Transverse 10µm cryosections from 12 week (A-B) and 30 week (C-F) old wildtype (A,C,E) and 
FKRPMD (B, D, F) diaphragm (A-D) and rectus femoris (E,F) were immunolabelled with an 
antibody against laminin α4.  Immunolabelling with this antibody was confined to the capillaries 
and nerves of wild type muscle, whereas immmunolabelling was observed at the basement 
membrane of small diameter fibres in the FKRPMD diaphragm and rectus femoris at 12 and 30 
weeks of age.  By 30 weeks of age laminin α4 was also evident at the basement membrane of 
larger diameter fibres.  Scale bar represents 50µm.   
 
Figure 5. FKRPMD LARGE histology. 10µm cryosections from FKRPMD (A,C,E,G) and 
FKRPMDLARGE (B,D,F,H) diaphragm (A-B), soleus (C-D) gastrocnemius (E-F), and tibialis 
anterior (G-H) at  30 weeks of age stained with haematoxylin and eosin (A-H).  All muscles 
showed a marked variation in fibre size, the presence of degenerative fibres infiltrated with 
macrophages and an increase in centrally nucleated fibres relative to the FKRPMD.  I-K show 
Alizarin Red labelling of wildtype (I), FKRPMD (J) and FKRPMDLARGE (K) diaphragm, with a 
greater incidence of calcium deposits (red) observed in the FKRPMDLARGE relative to FKRPMD.  
(L) is an image of a 30 week old FKRPMDLARGE gastrocnemius, showing an example of split 
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muscle fibres.  In images A-H and L scale bar represents 50µm. In I-K scale bar represents 
100µm.  
 
Figure 6. Immunolabelling showing a decrease in IIH6, a reduction in laminin α2 and 
increase in laminin α4.  
Transverse 10µm cryosections of the gastrocnemius (A-D) and diaphragm (E,F) of wildtype 
(A,C,E) and FKRPMDLARGE (B,D,F) mice, immunolabelled with IIH6 (antibody against 
glycosylated α-DG) (A,B), laminin α2 (C,D) and laminin α4 (E,F). IIH6 and laminin α2 
immunolabelling was increased in the FKRPMDLARGE mice relative to wildtype mice.  Laminin 
α4 can be seen at the muscle fibre basement membrane of FKRPMDLARGE mice whilst it is 
confined to the capillaries of wild type mice.  Scale bar represents 50µm. 
 
Figure 7. Ligand binding and quantitative analysis of split fibres and central nucleation. 
Western blot of α and β DG of WT, FKRPMD, FKRPMDLARGE (A) and laminin overlay assay of 
wild type, wild type overexpressing LARGE, FKRPMD and FKRPMDLARGE (B). As can be seen 
transgene expression in either the wild type or FKRPMD gives rise to an increase in laminin 
binding relative to wild type confirming that expression of the transgene led to the 
hyperglycosylation of α-DG.  The number of split fibres in the gastrocnemius of 12 week old 
wildtype (n=3), FKRPMD (n=3) and FKRPMDLARGE (n=3) was quantified and is shown in a 
histogram (C).  The results of a one-tailed Mann-Whitney test are shown * 0.01≤p<0.05, 
illustrating a significant increase with the overexpression of LARGE on the FKRPMD 
background.  (D) Counts of central nucleation were carried out on transverse 10µm cryosections 
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of 12 and 30 week wildtype, FKRPMD and FKRPMDLARGE diaphragm, gastrocnemius and 
soleus.  Muscle fibres with central nuclei were counted and expressed as a percentage of the total 
number counted (approximately 500 for the soleus, 1500 for the diaphragm and 2000 for the 
gastrocnemius).  The results of the Generalised Estimating Equations Statistical test are shown as 
a multiple line graph.  This model shows age, muscle and genotype are significant interacting 
factors on the percentage of centrally nucleated muscle fibres. The FKRPMD data shown in 
Figure 2 has been included to facilitate comparisons between the FKRPMD and FKRPMDLARGE 
models. 
 
Figure 8. In vivo assessment of muscle force production following eccentric contractions. 
Tibialis anterior muscles from 20 to 22 week old female FKRPMD (n=8), FKRPMDLARGE (n=5) 
and wild-type (non-transgenic) mice (n=7) underwent a series of 10 eccentric contractions in situ 
utilising a stretch of 15% of optimum muscle length.  The force produced by FKRPMD mice was 
not significantly different to that of wild-type animals and showed no significant drop from 
baseline.  However, FKRPMDLARGE mice showed a significant drop in force compared to the 
value at contraction 2 (P<0.05 for contraction 8, P<0.01 for contraction 9 and P<0.001 for 
contraction 10). FKRPMDLARGE mice were significantly weaker than wild-type at contractions 
7 to 10 (blue asterix symbols, * P<0.05, ** P<0.01) and weaker than FKRPMD mice (red asterix 
symbol, * P<0.05) after the tenth eccentric contraction.  The mean force produced after 10 
eccentric contractions was 118.46%, 105.83%, and 72.47 % of baseline for WT, FKRPMD, and 
FKRPMDLARGE mice respectively.  Values are presented as mean and S.E.M and data are 
analysed using a Repeated Measures One way ANOVA with Tukey’s post-hoc comparison. 
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Supplementary Figure 1 
10µm cryosections from FKRPMD (A,C,E,G) and FKRPMDLARGE (B,D,F,H) diaphragm (A-B), 
soleus (C-D) gastrocnemius (E-F), and tibialis anterior (G-H) at  12 weeks of age stained with 
haematoxylin and eosin.  All muscles showed a marked variation in fibre size and an increase in 
centrally nucleated fibres relative to the FKRPMD 
 
 
Abbreviations 
α-DG  α-dystroglycan 
AAV  Adeno-Associated Virus 
B3GNT1 Beta-1,3-N-Acetylglucosaminyltransferase 1 
CMD  Congenital Muscular Dystrophy 
DG  Dystroglycan 
DOLK  Dolichol Kinase 
DPM2  Dolichyl-Phosphate Mannosyltransferase Polypeptide 2 
DPM3  Dolichyl-Phosphate Mannosyltransferase Polypeptide 3 
ES  Embryonic Stem 
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FCMD  Fukuyama Congenital Muscular Dystrophy 
FKT  Fukutin 
FKRP  Fukutin Related Protein 
FKRP
KD 
FKRP knock down 
FKRPMD FKRP muscular dystrophy 
GalNAc N-Acetylgalactosamine 
GMPPB GDP-mannose pyrophosphorylase B 
GTDC2 Glycosyltransferase-Like Domain Containing 2 
ISPD  Isoprenoid Synthase Domain Containing 
LARGE  Like-acetylglucosaminyltransferase 
LG  Laminin globular 
LN  Laminin N-terminal 
LGMD Limb girdle muscular dystrophy 
MDC1D Congenital Muscular Dystrophy Type 1D 
MEB  Muscle Eye Brain Disease 
POMT1 Protein O-mannosyl-transferase 1 
POMT2 Protein O-mannosyl-transferase 2 
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POMGnT1 Protein O-mannose beta-1,2-N-acetylglucosaminyltransferase 
RT PCR Reverse Transcriptase Polymerase Chain Reaction 
Sox1  Sex determining region Y-box 1 
SGK196 Sugen Kinase 196 
TA  Tibialis Anterior  
TMEM5 Transmembrane Protein 5 
WWS  Walker-Warburg Syndrome 
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Real time gene expression analysis of FKRP in brain and muscle and histological evaluation of FKRPMD brain. 
86x83mm (300 x 300 DPI)  
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Body weight and histological analysis of muscle at 6, 12 and 20 weeks.  
156x135mm (300 x 300 DPI)  
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Immunolabelling and Western blot analysis of FKRPMD muscle.  
97x53mm (300 x 300 DPI)  
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Laminin α4 immunolabelling of FKRPMD and wild type controls.    
202x228mm (300 x 300 DPI)  
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FKRPMD LARGE histology.  
107x64mm (300 x 300 DPI)  
 
 
Page 46 of 58Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Immunolabelling showing a decrease in IIH6, a reduction in laminin α2 and increase in laminin α4.  
135x101mm (300 x 300 DPI)  
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Ligand binding and quantitative analysis of split fibres and central nucleation.  
108x78mm (300 x 300 DPI)  
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In vivo assessment of muscle force production following eccentric contractions.  
72x56mm (300 x 300 DPI)  
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Reviewer: 1  
This is an interesting paper in which the authors create a new FKRP disease model for the 
dystroglycanopathies and then test the therapeutic efficacy of LARGE overexpression in that model 
using transgenic mice. Brown and colleagues had previously made an FKRP knockdown mouse model 
by inserting a floxed neo cassette into intron 2 of the mouse FKRP gene. This led to reduced FKRP 
gene expression and reduced functional glycosylation of dystroglycan, causing defects in cortical 
migration akin to human disease with perinatal lethality. Here, they have deleted the floxed allele 
that knocks down FKRP expression in the brain using Sox1-Cre to rescue knockdown in 
neuroectoderm. This allows for normal brain development yet maintains an LGMD2I-like muscular 
dystrophy. This alone is worthy of publication, but the authors then go on to cross this model to a 
constitutively driven LARGE transgenic mouse line that they previously showed has relatively normal 
muscle function but can increase alpha DG glycosylation. There are at least three groups of studies 
suggesting that LARGE overexpression may increase aDG glycosylation in various forms of 
dystroglycanopathy, including some where LARGE mutations are not the cause of the disease. Unlike 
those studies, the work here suggests that overexpression of LARGE makes muscle disease worse, 
leading to increased histopathology, particularly intracellular calcium deposits, and increase lethality 
(around 27 weeks). The author’s argue that the timing of LARGE overexpression may be important, 
as may other matters, and so one must think more carefully about ideas utilizing LARGE for therapy 
in these diseases. The concepts presented here are very worthy of publication. The work, however, 
would need to be significantly revised prior to being found acceptable for HMG. The issues involved 
include data presentation, data interpretation and lack of data.  
 
We thank the reviewer for their positive and constructive comments regarding our manuscript and 
have addressed their comments as follows:- 
 
1. Each figure is unnecessarily difficult to read. The muscles, genotypes, and ages should be labeled 
on the panels to allow an easier understanding of what is presented.  
 
We have now added the muscle, genotype and ages to each of the panels in Figures 2, 3, 4 and 5 
and agree that this makes these figures much easier to understand.   
 
2. For Figure 1, we should see much more data on the relationship between gene knockdown and 
phenotype. Is FKRP expression in FKRP MD muscle lower, greater, or the same as expression in FKRP 
KD muscle? This needs to be shown.  Is the Sox1-Cre rescue of FKRP expression specific to brain (what 
about spinal cord, heart, liver, kidney, etc)? This is particularly important, given that the authors will 
later show that a Tg mice constitutively overexpressing LARGE makes disease worse.  
 
We have now added a histogram depicting a QPCR of Fkrp in the brain at E15.5 in the FKRPKD 
mouse so that the percentage knock-down can be seen to be similar in the FKRPMD and FKRP
KD 
mice. We have also carried out similar analyses in other tissues including liver, kidney and spleen, 
the results of which are shown below. As can be seen this is statistically significant in spleen, brain 
and muscle but there is a trend for lower levels in the other tissues which requires more analyses 
if it is to be verified given the size of the error bars. For this reason we would prefer not to include 
these preliminary analyses in the paper. We have also observed that IIH6 is reduced in the heart of 
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the FKRPMD. Overall these data are consistent with what is known about the pattern of activity of 
the Sox1.  
 
 
 
If LARGE is overexpressed everywhere, how will we know its relationship to FKRP in other organs if 
we don’t know if FKRP is lower or not.  
 
Whilst we agree with the referee that the knock-down of Fkrp in other tissues is of relevance given 
that LARGE was expressed constitutively, the focus of our study was the up-regulation of LARGE 
on a background of FKRP deficiency in skeletal muscle, and our paper specifically focuses on the 
worsening of the skeletal muscle phenotype. The overexpression of LARGE was achieved under 
the CAAGs promoter which gave rise to varying levels of LARGE in each tissue, with the highest 
levels evident in skeletal muscle - in comparison to skeletal muscle levels were approximately 4x 
lower in the heart and 10x lower in brain, kidney and liver (Brockington et al. PLoS One. 2010 Dec 
28;5(12).  The overexpression of LARGE in other organs relative to the levels of Fkrp is of obvious 
interest to the disease phenotype, but is beyond the remit of the present study which as the 
reviewer notes already includes the generation of a new model for this group of diseases and the 
testing of a possible therapeutic strategy.  
 
The staining for IIH6 in the pial basement membrane needs to be more convincing. Previously, the 
authors have used double IF with laminin and IIH6, and laminin and beta DG, to show localization at 
the pial BM. Why not here as well? Also, just showing FKRP MD and not other genotype for this just 
isn’t convincing. Please show FKRP KD and WT for comparison, just as in other parts of the figure.  
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We have now generated a new figure which includes WT, FKRP
KD
 and FKRPMD immunolabelled for 
IIH6. We hope that the staining at the pial basement membrane is clearer as we have chosen to 
zoom in on the cortical surface in all these images. We have used paraffin embedded sections for 
this part of the figure due to IIH6 showing more clearly using the Dako Envison kit than it does 
with immunofluorescence which we have used previously. As can been seen the FKRP
KD
 shows a 
disruption of neuronal layering and an absence of IIH6 labelling at the pial basement membrane. 
Pan laminin immunolabelling shown in the lower half of the new figure is on frozen sections of 
FKRP
KD
 heterozygote (heterozygotes display no disease phenotype), FKRP
KD
 and FKRPMD. This 
shows clearly that the continuity of the pial basement membrane has been restored in the FKRPMD 
such that it is indistinguishable from the FKRPKD heterozygote (which shows no disease 
phenotype).  We hope that this figure is now acceptable to the reviewer. 
 
3. In Figure 2, it would be better to show all of the data at different ages in the same graph, with 
statistical comparisons between ages for each muscle described within the figure, and also with 
statistical comparisons between genotypes.  
 
We have now revised the graph so the figure now contains one combined bar graph with the data 
from both ages.  Before our first submission we consulted a statistican and analysed our data with 
a Generalised Estimating Equations model.  This showed that age, muscle and genotype were all 
interacting factors significantly affecting the percentage of centrally nucleated fibres.  We thank 
the reviewer for highlighting that the results of this analysis were not presented clearly so we 
have revised the text and included a line graph, which we were advised is the best way to present 
this analysis. 
 
 
4. The magnifications in Figure 3 are oddly chosen. A and B show a very low power images, where the 
soleus shows IIH6 staining but the rest of the gastroc does not? This is not helpful and likely not true. 
Ideally, even in the FKRP MD muscles, at high power, one should be able to show IIH6 staining in an 
intramuscular peripheral nerve to demonstrate that the antibody worked. There are no clear positive 
controls for staining shown here.  
 
The images we previously showed were an accurate reflection of the difference in intensity that 
we always see in the soleus compared to the gastrocnemius. We have nonetheless removed this 
image from Figure 3 and instead showed an image of the WT and FKRPMD triceps in Figure 6 
labelled with both laminin α2 and IIH6. Two nerves can clearly be seen with the laminin α2 
immunolabelling but are barely detectable with IIH6 (some faint labelling is visible around the 
endoneurium) suggesting that this is not an ideal internal control as Fkrp expression may not have 
been restored in the intramuscular nerves. All sections included in this Figure were labelled at the 
same time, collected using the same exposure times and include sections of FKRPMDLARGE which 
we hope convinces the reviewer that our staining has worked. 
 
5. The laminin alpha 2 staining is just not convincing. The authors suggest that FKRP MD muscle has 
altered laminin alpha 2 staining, with higher expression in regenerating fibers and lower expression 
on mature fibers. This just cannot be ascertained from what is shown. One would need co-stains 
(markers of regenerating versus mature muscle) and blots to further this conclusion. Also, the title of 
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this section refers to laminin “deposition”, which is only a component of overall expression shown by 
staining.  
 
We have now immunolabelled for developmental myosin as the reviewer suggests and find that 
very few fibres express developmental myosin. Instead those groups of fibres showing an 
apparent increase in laminin alpha 2 expression are associated with an increase in cellular activity. 
We have prepared a new figure showing the Hoechst labelled nuclei together with the laminin 
alpha 2 which clearly illustrates this. We have also added images using a look up table which 
provides a more clear illustration of variations across the section which are much less apparent in 
the control muscle. Western blots would not add any useful information regarding this variation in 
laminin alpha 2 labelling due to it necessarily being based on extracts of the entire muscle. We do 
nonetheless thank the reviewer for his/her comments regarding this aspect as the changes we 
have undertaken have greatly improved the clarity of this figure. 
 
6. Similarly, the laminin alpha 4 staining in Figure 4 is unconvincing. It would not be surprising to see 
increased laminin alpha 4 staining in regenerating muscle that is unrelated to dystroglycan. 
Dystroglycan deficient dystrophic muscles show tons of laminin alpha 4 staining. Some co-staining to 
define myofiber subsets and also blots would be needed to assess increased or decreased matrix 
expression.  
 
Dystrophic muscle, including laminin α2 deficient muscle (as referenced in the paper) shows an 
altered deposition of laminin α4, and we accept that this feature is not unique to disorders linked 
to dystroglycan.  In addition we do not claim that overall levels of laminin alpha 4 are dramatically 
increased in the FKRPMD but rather that in specific areas its distribution pattern is altered.  
 
Further work has now shown that in the FKRPMD laminin α4 immunolabelling is identified at the 
basement membrane of muscle fibres in discrete focal areas and that these are not necessarily 
those which are regenerating (as defined by the distribution of developmental myosin).  Instead 
these areas tend to be associated with increased cellular activity as with laminin α2 
immunolabelling. The images shown of the FKRPMD are representative of these areas. We have 
now modified Figure 6 to show that these areas are greatly increased as is the intensity of labelling 
in the FKRPMDLARGE relative to the FKRPMD. Western blotting is not sufficiently sensitive to be 
useful to document such changes in distribution given that it is based on whole protein extracts.   
   
7. Figure 5 would be much more convincing if FKRP MD and FKRP MD LARGE muscles were shown 
together, size- and age-matched. The figure needs to be labeled so that it can be read without having 
to go to the legend. This is the most important result in the paper, yet it is not as convincing as it 
might be. It is very interesting that Alizarin red labeling is dramatically increased in the one FKRP MD 
LARGE image shown in the diaphragm. The extent of this finding should be more carefully explained, 
as it may be highly significant. Is this true in all muscles? Is it true only in regenerating fibers? 
 
In order to allow for an easier comparison of the FKRPMD and FKRPMDLARGE muscles we have now 
changed this image to show size and age matched images of each genotype and labelled the 
panels to facilitate comparisons. For the sake of clarity we show the muscle at 30 weeks of age 
and have moved all images at 12 weeks to supplementary data. 
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We agree with the reviewer that the increased Alizarin Red staining in the FKRPMDLARGE mice is 
interesting.  This increased Alizarin Red staining was observed in the 4 FKRPMDLARGE mice and 3 
FKRPMDLARGE mice examined at 12 and 30 weeks of age respectively.  Both the diaphragm and the 
gastrocnemius were examined and age-matched FKRPMDLARGE mice had larger deposits than 
FKRPMD mice. The deposits in the diaphragm also appeared larger than those in the gastrocnemius. 
Alizarin Red staining detects calcium precipitates, so it is not a phenomenon that we would expect 
be restricted to regenerating fibres.  Instead we view it as another histological indicator of muscle 
fibre degeneration which appears worse with the up-regulation of LARGE. 
 
8. Figure 7 is confusing. In A, the LN overlay, what is the difference between the last three lanes? 
Where is the IIH6 and beta DG blot that should go along with the ligand binding data?  
 
We have now included Western blot of IIH6 and β dystroglycan which shows α-dystroglycan 
hyperglycosylation in the FKRPMDLARGE in the absence of any change in the molecular weight of β- 
dystroglycan. Regarding the laminin overlay the last three lanes represent three different 
FKRPMDLARGE mice and show how consistent the laminin binding is between individuals. 
 
Why is LN binding lower in some of the FKRP MD-LARGE lanes than in WT LARGE?  
 
FKRPMD mice will have an altered glycosylation pattern of α-dystroglycan relative to wildtype mice.  
Although an up-regulation of LARGE has, as shown increased α-dystroglycan glycosylation over 
and above that of wildtype mice, the precise arrangement of these sugar groups may be different 
between WT LARGE and FKRPMDLARGE, due to the reduction in Fkrp expression in the latter but 
not the former. This may account for the altered laminin binding when comparing WT LARGE to 
FKRPMDLARGE animals on the laminin overlay.  
 
Equally important here is to confirm that the FKRP MD-LARGE line made does not show an increased 
reduction in FKRP expression relative to FKRP MD. This data is not in the paper, but one assumes 
these are not pure-bred lines from a Tg cross.  
 
We can confirm that these mice were not pure-bred lines from a transgenic cross, they were 
maintained on a mixed background.  The knock-down in the FKRPMD is achieved via the insertion 
of a neomycin resistance cassette in intron 2 of the Fkrp gene. Unpublished data from our 
laboratory suggests that incorporation of the neo cassette into the Fkrp transcript leads to 
nonsense mediated decay. Whilst it is conceivable that the percentage knock-down might differ as 
a consequence of the genetic background; we believe that any differences between the different 
genetic backgrounds would not be detectable in view of the very low levels of endogenous Fkrp. 
Nonetheless we have added a sentence in the discussion to highlight this possibility.  
 
9. The functional data leaves a lot to be desired. Figure 9 shows force drop during eccentric 
contractions in the TA muscle measured in situ. FKRP MD and FKRP MD LARGE mice are compared to 
WT, with FKRP MD LARGE showing a mild (ca. 20%) decline by the 10th contraction. As WT LARGE 
mice have been reported to have some mild physiological deficits, not showing data on these mice 
here is will raise suspicion. The n also needs to be raised beyond 5 for the FKRP MD LARGE group. 
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Given the errors, the entire change here could be due to one animal. Some explanation is warranted 
as to distribution by animal to better understand this data. It is also just odd to show physiology data 
on a muscle where no pathology data are shown.  
 
We previously tested the possibility that LARGE overexpression may alter the resistance of TA 
muscles to contraction-induced injury which is the work that the reviewer refers to. In this study 
the TA muscles were subjected to a series of lengthening contractions and the impact of these 
repeated lengthening contractions on force generation measured over time (Brockington et al., 
PLoS One. 2010 Dec 28;5(12):Transgenic overexpression of LARGE induces α-dystroglycan 
hyperglycosylation in skeletal and cardiac muscle). We reported no significant difference in 
resistance to contraction-induced injury in 2 month old LARGE transgenic mice compared to 
control mice although at 8 months of age, LARGE transgenic mice developed a significant 
susceptibility to contraction-induced injury, as demonstrated by a 30% greater decline in force 
generation compared to controls following 8 successive lengthening contractions. This work is 
published, moreover the deficit was only seen in older animals and so we felt no requirement to 
repeat these analyses in the present study which was based on animals at 20 weeks.    
 
Regarding the possibility that with these error values one animal could have contributed to the 
statistical significance of this result; we have now re- analysed the data removing one of the 
animals in which the response was more marked relative to the others. However, there is still a 
significant difference between wild type and FKRPMDLARGE animals at eccentric cycle 9 (p=0.042) 
and at eccentric cycle 10 (p=0.019). Our experience with these animals at this age and also data we 
have at other ages indicates that the response is variable between individuals and that this should 
be reported as such. 
 
The physiological data was performed on the TA muscle and quite rightly the reviewer draws 
attention to the fact that we failed to present the pathology of this muscle, we have therefore 
now included images of this muscle in Figure 5. 
 
Minor:  
 
1. The authors need to state that Campbell and colleagues have shown that LARGE is a Xyl GlcA 
tandem glycosyltransferase. They have also recently shown that SGK196 is the phosphor-mannose 
transferase, not LARGE, as stated here.  
 
In response to this very important point we have modified the paragraph on pages 3-4 to read: 
“Whilst the precise pathway in which these proteins function is unclear, recent work suggests that 
SGK196 is a glycosylation specific O-mannose kinase and that FKRP, FKTN, TMEM5, B3GNT1 and 
LARGE all contribute to the generation of an extracellular matrix binding moiety on the resulting 
phosphorylated core M3 glycan (38). The loss of matrix binding is associated with a profound 
reduction in the binding of either IIH6 and/or VIA4-1 antibodies to α-dystroglycan (40)”.  
 
and on page 5:  
“Whilst there have been two recent reports of the successful restoration of functional 
glycosylation and amelioration of the muscle pathology by AAV vectors carrying either FKRP (41) 
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or fukutin (42), one of the most promising forms of therapy proposed in recent years for the 
dystroglycanopathies is the up-regulation of LARGE; a bifunctional glycosyltransferase that 
alternately transfers xylose and glucuronic acid to generate a heteropolysaccharide that confers α-
dystroglycan with its ligand binding properties (43).” 
 
2. Page15, Introduction. Willers et al 2012 have shown that LARGE does not affect glycosylation of 
some POMT1, FKRP and FKTN mutations. This should be cited and stated.  
 
We have now altered the paragraph on page 5 to read as follows:- 
“This is based on observations showing that LARGE is able to restore α-dystroglycan glycosylation 
and functional laminin binding to cells taken from patients with congenital muscular dystrophy 
(FCMD, MEB and WWS), seemingly irrespective of the gene involved (43). Whilst this response 
may be dependent on the availability of O-mannosyl phosphate acceptor sites (32), this strategy is 
still considered as being potentially useful for a wide range of patients.” 
 
and on page 15: 
“Whilst more recent work now demonstrates that the ability of LARGE to hyperglycosylate α-
dystroglycan is dependent on the availability of O-mannosyl phosphate acceptor sites and 
correlates with the severity of the clinical phenotype (32); this strategy is still considered as being 
potentially useful for a wide range of patients”. 
 
The Willer paper has now been added to the bibliography (32). 
 
3. Page 18 Title, “deposition” should be replaced by “expression”.  
 
This change has now been made to the manuscript.  
 
4. Page 27. The authors have not shown a reduction in O-mannosylation in their mouse model. Best 
to eliminate that sentence.  
 
We have now changed the sentence on page 27 to read “a reduction in α-dystroglycan 
glycosylation”.   
 
Reviewer: 2  
The manuscript “The transgenic expression of LARGE exacerbates the muscle phenotype of 
dystroglycanopathy mice” by Charlotte Whitmore et al describes some very interesting observation in 
the FKRP mutant mouse model. The lack of FKRP expression in the CNS cause embryonic lethality, but 
this is rescued by the removal of the neo cassette specifically in CNS, leading to the restoration of 
functional glycosylation of alpha-DG in the CNS. The mild dystrophic phenotype in skeletal muscles of 
the FKRPMDis a small surprise as the mice apparently completely lack functional glycosylated alpha-
DG. The demonstration that LARGE over-expression rescues the expression of functional glycosylated 
alpha-DG, but results in worsening of muscle pathology is significant, implying that the strategy of 
LARGE upregulation as a therapy to dystroglycanopathies requires careful reconsideration. This is 
perhaps not surprising as the functions of LARGE remains poorly understood.  
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The data presented in the manuscript are valid and mostly convincing. However, several issues need 
the authors’ attention.  
 
We thank this reviewer for the positive comments on our manuscript and address his/her specific 
concerns as follows:- 
 
1) Demonstration the restoration of functional glycosylation of a-DG by western blots is important. 
Such results can provide vital information to assess the type of glycosylation on the a-DG by the 
LARGE over-expression. However, the only wb data in figure 7 is the laminin O/L. In the Figure, 
signals for laminin binding can hardly be observed in WT muscles and there is no molecular marker to 
define sizes of the signal. The quality of the western blot should be improved and a western blot with 
IIH6 should be provided for readers to understand the changes with the expression of the transgene 
in comparison to the wild type functionally glycosylated a-DG.  
 
We have now included a IIH6 Western Blot to match the overlay and annotated the figure to show 
the sizes.   
 
2) The author described the pathology of the new FKRPMD in skeletal muscles, but there is no 
description of the cardiac muscle. This is important for assessing the impact of LARGE over-
expression on lifespan. The mice as described by the authors have quite mild pathology in 
diaphragm. It is therefore possible that a shortened lifespan of the FKRPMD/LARGE is the result of 
transgene expression on cardiac muscle. The authors must have examined the cardiac muscle, and if 
so, should present the data.  
 
We have made preliminary studies of the cardiac muscle and found no histopathological 
abnormalities in the FKRPMD. In some of the FKRPMDLARGE we did see more evidence of pathology 
at 30 weeks. However, in the absence of functional data, which we considered outside of the 
remit of the present paper, we did not feel that we had sufficient evidence to attribute such 
changes with a role in the shortened lifespan of these mice.  We agree with the reviewer that this 
is nonetheless an important issue and we intend to follow this up in a subsequent study. 
 
3) The reasons for FKRPMD-LARGE mice present worse phenotype than the FKRPMD mice do are not 
clear. The authors put up two hypotheses. However, genetic background affects phenotype of FKRP 
mutation as well. The authors should mention that the genetic background of the hybrid FKRPMD-
LARGE could also be a factor for the severer phenotype even without LARGE over expression.  
 
Whilst the FKRPMDLARGE transgenic has a different background to the FKRPMD mouse histological 
evaluation of wildtype LARGE overexpressing littermates on this new genetic background failed to 
identify any signs of a muscle pathology, suggesting that it is an interaction between a deficiency 
of Fkrp and overexpression of LARGE that is the underlying cause of the worsened phenotype.  
We have therefore added the following sentences to the manuscript: 
“Finally it should also be noted that as a consequence of the transgenic approach adopted here, 
the FKRPMDLARGE mice are on a different background to the FKRPMD mouse. However, we consider 
this an unlikely cause of the worsened phenotype since histological evaluation of wildtype LARGE 
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overexpressing mice on this new genetic background failed to identify any evidence of a 
dystrophic pathology”. 
 For the Figure 6, the title sentence needs to be corrected by adding a , and an and. “Immunolabelling 
showing a decrease in IIH6, reduction in laminin α-2, and increase in laminin α-4”. 
 
We have now altered the figure title as suggested by the reviewer. 
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